Stay tuned for our LIVE OncLive News Network coverage straight from the #ASH18 conference floor! 

Dr. Modest Discusses the German AIO KRK0110 Study in CRC

Dominik P. Modest, MD
Published: Friday, Aug 18, 2017



Dominik P. Modest, MD, University of Munich, discusses the German AIO KRK0110 study in metastatic colorectal cancer (CRC).

AIO KRK0110 is a randomized phase III study of fluoropyrimide plus bevacizumab (Avastin) versus fluoropyrimide plus irinotecan and bevacizumab as first-line therapy for metastatic CRC.

This sequence study aims to answer the question of de-escalation in this patient population.
 


Dominik P. Modest, MD, University of Munich, discusses the German AIO KRK0110 study in metastatic colorectal cancer (CRC).

AIO KRK0110 is a randomized phase III study of fluoropyrimide plus bevacizumab (Avastin) versus fluoropyrimide plus irinotecan and bevacizumab as first-line therapy for metastatic CRC.

This sequence study aims to answer the question of de-escalation in this patient population.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™ Decision Points in Advanced NSCLC: Assessing Treatment Options Beyond Disease ProgressionNov 30, 20181.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x